Intellia Therapeutics Inc

NTLA

Equity

ISIN null / Valor 32256913

NASDAQ (2025-11-21)

USD 8.21+2.11%

Intellia Therapeutics Inc
UMushroom community rating:

4.00 2 votes No rating yet

NegativeNeutralPositive

About company

Intellia Therapeutics Inc is a biotechnology company focused on developing curative genome editing treatments using CRISPR/Cas9 technology. Founded with the mission to transform the lives of people with severe diseases, Intellia collaborates with partners like Regeneron to explore in vivo applications of genome editing. The company's work in harnessing the potential of CRISPR to make specific changes in the DNA of humans, animals, and plants has captured global attention for its potential to revolutionize disease treatment. Led by co-founder Jennifer Doudna, Intellia is at the forefront of the genome editing field, working towards developing innovative therapies for a range of genetic disorders.

Summarized from source with an LLMView SourceSector: Technology

Cash Position

As of June 30, 2025, Intellia Therapeutics Inc. held approximately $630.5 million in cash, cash equivalents, and marketable securities, a decrease from $861.7 million at the end of December 2024.

Operational Funding

The current cash reserves are expected to fund the company’s operations into the first half of 2027 and support the anticipated first commercial launch. The decrease in cash was primarily due to $65.0 million in non-recurring cash payments related to portfolio prioritization, workforce reduction, and real estate costs.

Financial Runway

Intellia Therapeutics Inc. maintains a solid financial runway, ensuring sustained investment in its clinical programs and strategic initiatives through mid-2027.

Summarized from source with an LLMView Source

Key figures

-40.5%1Y

-83.0%3Y

-74.6%5Y

Performance

103%1Y

77.4%3Y

82.0%5Y

Volatility